Table 4.
Risk factors of liver fibrosis in metabolic dysfunction-associated fatty liver disease patients with hepatitis B virus infection.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Old age | ||||
| No | Ref | |||
| Yes | 2.194 (0.689–6.993) | 0.184 | – | – |
| Male | ||||
| No | Ref | |||
| Yes | 1.180 (0.457–3.044) | 0.732 | – | – |
| BMI > 23 kg/m2 | ||||
| No | Ref | |||
| Yes | 1.141 (0.307–4.244) | 0.844 | – | – |
| Hypertension | ||||
| No | Ref | |||
| Yes | 1.479 (0.786–2.782) | 0.225 | 2.640 (1.091–6.368) | 0.031 |
| T2DM | ||||
| No | Ref | |||
| Yes | 5.540 (1.72–17.63) | 0.004 | 4.939 (1.121–21.796) | 0.035 |
| Hypertriglyceridemia | ||||
| No | Ref | |||
| Yes | 0.821 (0.451–1.495) | 0.591 | – | – |
| Hypercholesterolemia | ||||
| No | Ref | |||
| Yes | 1.187 (0.458–3.079) | 0.725 | – | – |
| Hyperuricemia | ||||
| No | Ref | |||
| Yes | 1.840 (0.909–3.723) | 0.9 | – | – |
| High LDL-c | ||||
| No | Ref | |||
| Yes | 0.913 (0.503–1.657) | 0.764 | – | – |
| Low HDL-c | ||||
| No | Ref | |||
| Yes | 0.907 (0.433–1.902) | 0.796 | – | – |
| HBeAg positive | ||||
| No | Ref | |||
| Yes | 0.853 (0.461–1.545) | 0.6 | – | – |
| HBV DNA positive | ||||
| No | Ref | |||
| Yes | 0.700 (0.323–1.516) | 0.366 | – | – |
| Elevated ALT | ||||
| No | Ref | |||
| Yes | 1.271 (0.662–2.441) | 0.471 | – | – |
| Elevated AST | ||||
| No | Ref | |||
| Yes | 1.457 (0.794–2.673) | 0.224 | – | – |
| Elevated GGT | ||||
| No | Ref | |||
| Yes | 2.991 (1.612–5.550) | 0.001 | 3.980 (1.735–9.132) | 0.001 |
BMI body mass index, T2DM type 2 diabetes mellitus, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, HBeAg hepatitis B e-Antigen, HBV DNA hepatitis B virus deoxyribonucleic acid, GGT gamma-glutamyl-transferase, OR odds ratio, CI confidence interval.